Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aceclofenac (2-[(2,6-dichlorophenyl) amine]phenylacetoxyacetic acid; CAS 89796-99-6) is a new orally effective non-steroidal anti-inflammatory agent of the phenylacetic acid group which showed remarkable anti-inflammatory, analgesic, and antipyretic properties. Hence, aceclofenac possesses a potent inhibitory activity in several models of acute and chronic inflammation in rodents, and resembles indometacin and diclofenac in its pharmacodynamic profile, being superior to naproxen and phenylbutazone. In addition, aceclofenac was found to be highly active against sodium urate-induced synovitis in dogs and adjuvant-induced polyarthritis in rats, both prophylactically and therapeutically. The analgesic effect of aceclofenac on the pain elicited by chemical and mechanical stimuli was nearly equal to or slightly better than that of indometacin and diclofenac. Fever induced by brewer's yeast injection in rats was also markedly suppressed by aceclofenac. In contrast, the acute gastric ulcerogenic activity of aceclofenac was about 2, 4 and 7-fold lesser than that of naproxen, diclofenac, or indometacin, respectively. As a consequence of its high anti-inflammatory activity and lower potential for gastric damage aceclofenac exhibited the most favourable therapeutic ratio in comparison with indometacin, diclofenac, naproxen, and phenylbutazone. These data indicate that aceclofenac could be a potent anti-inflammatory and analgesic agent with a wide margin of safety in clinical practice.
 ...
PMID:Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. 181 28

The activity and tolerability of aceclofenac, a new arylacetic anti-inflammatory drug, was assessed in the treatment of post-episiotomal pain in a controlled double-blind study with paracetamol. Aceclofenac was administered in single 100 mg doses and paracetamol in single 650 mg doses (both drugs in tablet form) to 60 women aged between 18 and 38 years with post-episiotomal pain. They were randomised into two groups of 30 patients. The severity of the pain was assessed by the patients using an analog visual test (Huskisson's test) before treatment and 0.5, 1,2,3,4,5 and 6h after receiving the drug. At the end of the study, the investigator questioned the patients about the evolution of their pain and any side-effects that might have appeared during the 6 h of observation. On the basis of their replies, the investigator evaluated the pain on a semi-quantitative scale of 5 points. The tolerability was assessed on the basis of the appearance of any undesired effects. The patients treated with drug A* showed a progressive and marked reduction of their pain with a significant difference from the baseline score after the second hour of observation (Huskisson's test) and after the first hour (physician's assessment with the 5-point scale), respectively. The antalgic effect of drug B showed a similar evolution over time to drug A but the analgesic efficacy seemed to be much less.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Evaluation of the analgesic activity and tolerability of aceclofenac in the treatment of post-episiotomy pain. 266 7

The efficacy and safety of 100 mg aceclofenac twice daily was investigated in 73 patients with active rheumatoid arthritis in a multi-centre, double blind, randomised, parallel group, placebo controlled study over a period of 4 weeks. Treatment with aceclofenac was effective in improving the Ritchie articular index (predetermined primary end point), duration of morning stiffness, joint swelling, ARA functional class, patient's and physician's global assessments, and pain. All these improved to a significantly (P < 0.05) greater extent than in placebo-treated patients. Grip strength showed a significant improvement from baseline in the aceclofenac-treated group and this was greater than the improvement measured in placebo treated patients. No significant difference was detected between the treatment groups for the number of subjects reporting an adverse event. Aceclofenac administered orally at 100 mg twice daily for four weeks thus produced significant improvements in patients with active rheumatoid arthritis. This treatment was well tolerated with an adverse event profile similar to that of placebo.
 ...
PMID:Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory. 885 64

The efficacy and safety of aceclofenac (100 mg bid), a new nonsteroidal anti-inflammatory/anti-rheumatic agent, were compared with those of naproxen (500 mg bid) in a multi-centre, twelve-week, randomized, double-blind, parallel-group clinical trial in outpatients with active osteoarthritis of the knee. 190 patients received aceclofenac, 184 naproxen. The two treatments were compared on the basis of several characteristic clinical features of osteoarthritis of the knee, including various pain measurements. In both groups, the treatment resulted in a significant reduction of the pain at rest, pain on movement and the pain from pressure on the joint, 76-86% of aceclofenac patients reporting reduction in pain after 12 weeks. Three-quarters of the aceclofenac-treated patients had an accompanying reduction in joint swelling and 81.4% in knee function capacity, up to complete freedom of movement. Joint stiffness, which at baseline lasted 20 minutes, was reduced in the aceclofenac group to 10 minutes. A statistically significant difference in the efficacy of the two drugs was not found. The 34 adverse drug effects documented in 24 (12.6%) of the aceclofenac patients were fewer than the 43 events in 30 patients (16.3%) reported for naproxen. The trend towards better tolerability of aceclofenac manifested itself above all in a lower total incidence of gastrointestinal side-effects. Aceclofenac is as effective as naproxen in the symptomatic treatment of osteoarthritis of the knee and is well tolerated in general.
 ...
PMID:Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. 913 23

Aceclofenac, a phenylacetic acid derivative, is a new nonsteroidal anti-inflammatory drug (NSAID). It is indicated in the symptomatic treatment of pain and inflammatory or degenerative arthropathies: osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, abarticular inflammations, posttrauma or postoperative inflammations. The usual oral dosage of aceclofenac is 100 mg twice daily in adults. Its clinical efficacy seems to be similar to that of other NSAIDs, but its safety profile, especially gastro-intestinal tolerance, appears to be better. Finally, in vitro studies suggested that aceclofenac may exert positive effect on cartilage matrix metabolism.
 ...
PMID:[Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)]. 1008 15

The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders. Aceclofenac has an outstanding anti-inflammatory profile, involving besides a classical inhibition of prostaglandins E2, a decrease in the expression of several cytokines including interleukin 1 and tumor necrosis factor alpha. It also inhibits activated oxygen species production and influences cells adhesion. Aceclofenac and its main metabolite, 4-hydroxyaceclofenac, has positive effects on cartilage anabolism combined with modulating effect of matrix catabolism. Clinically, aceclofenac has been consistently shown to have a similar efficacy than that of widely marketed NSAIDs and a tolerance profile at least as good, if not better than the profile observed for other NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. As of today, no head to head comparison between aceclofenac and coxibs have been performed, nor for efficacy neither for tolerance. The specific profile of aceclofenac makes this NSAID an interesting candidate for long-term treatment of chronic rheumatic disorders as well as for treatment of acute inflammatory episodes.
 ...
PMID:[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. 1152 98

A pan-European study involving 23407 patients with pain due to various inflammatory or degenerative rheumatic diseases was undertaken in Austria, Belgium, Germany and Greece, to evaluate overall pain relief and satisfaction with aceclofenac therapy. Aceclofenac was considered by patients to be a highly efficacious treatment with excellent and fast analgesic activity that was maintained throughout the study period. At the conclusion of the study, assessment of patient status, a parameter encompassing both efficacy against inflammatory pain and tolerability, by both patient and physician, was either much improved or improved in 84% of cases. These evaluations were similar irrespective of the country or whether the indication was acute (e.g. post-pain) or chronic pain (e.g. osteoarthritis). Patient satisfaction with, and compliance of, aceclofenac therapy was similarly impressive; 90% of patients were satisfied and over 90% of patients were treatment compliant. In combination with the recently published SAMM study results, the findings of the European Observational Cohort study validate aceclofenac, in everyday clinical practice, as an effective, well-tolerated and well-accepted therapy for both acute and chronic inflammatory and degenerative disease. The availability of a powerful anti-inflammatory agent with a low incidence of side-effects is of considerable value to both the patient and physician in the management of inflammatory pain. This objective has been fulfilled with aceclofenac therapy.
 ...
PMID:Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. 1209 24

Aceclofenac (Almirall Prodesfarma SA) is an oral NSAID that is effective in the treatment of painful inflammatory diseases and has been used to treat > 75 million patients worldwide. It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis. It also provides effective analgesia in other indications, such as dental or gynaecological pain, lower back pain and ear, nose and throat indications. Aceclofenac appears to be particularly well-tolerated amongst the NSAIDs, with a lower incidence of gastrointestinal adverse effects. This good tolerability profile results in a reduced withdrawal rate and hence greater compliance with treatment.
 ...
PMID:Aceclofenac in the management of inflammatory pain. 1516 79

The analgesic efficacy of aceclofenac in the control of pain after surgical extraction of impacted mandibular third molars was compared with its preoperative administration. Two groups of 20 patients each were medicated with 2 tablets of 100 mg aceclofenac taken orally either 1h before surgery or in the early postoperative period. All surgeries were performed by the same surgeon and the surgical technique was the same for all patients. Pain was assessed with a Visual Analogue Scale and a 0-4 Scale, as well as by counting the number of analgesic drug tablets taken after the surgery. Patients in the preoperative group took fewer tablets postoperatively and had a lower pain score both in the Visual Analogue Scale and the 0-4 Scale. This difference, however, was statistically significant only at 6h after surgery, which is the time of maximum pain for this surgical procedure. Aceclofenac was more efficient in controlling pain when administered before the surgery.
 ...
PMID:Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. 1627 69

The study is a prospective randomized double blind clinical trial comparing the efficacy of nonselective NSAIDs (Aceclofenac) and highly selective COX-2 inhibitors (Etoricoxib) in post extraction pain control. The primary efficacy was judged by overall assessment of onset and duration of analgesic effect and rate of decrease in pain intensity by a visual analogue scale over a 3-day investigation period. 100 patients were enrolled in the study (50 patients in aceclofenac group and 50 patients in etoricoxib group). Twice-daily dosage of aceclofenac 100 mg and etoricoxib 60 mg were recommended for the double blind study. 64 patients completed the study. Efficacy of pain control over baseline data documented in both the treatment groups were statistically significant (p<0.05). There was no significant difference between the two drugs.
 ...
PMID:Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial. 1637 92


1 2 Next >>